Keros Therapeutics, Inc. Stock Price, News & Analysis

Keros Therapeutics (NASDAQ: KROS) urges stockholders to vote "FOR" three director nominees at its upcoming Annual Meeting on June 4, 2025. The company is conducting a strategic review process, with an update expected by June 9, 2025, to evaluate options including potential sale, business combinations, pipeline investment, and/or capital return. Keros highlights its pipeline progress, including: KER-065 for Duchenne muscular dystrophy, advancing to Phase 2 in Q1 2026; elritercept (KER-050) licensed to Takeda in a deal worth up to $1.3B ($200M upfront + $1.1B in milestones); and cibotercept (KER-012) for PAH, with topline Phase 2 data expected in Q2 2025. The company faces opposition from ADAR1 Capital Management, which is pushing for immediate liquidation. The board emphasizes its independence (8 of 9 directors) and expertise in biotech/pharma sectors.

ADAR1 Capital Management, the largest shareholder of Keros Therapeutics (NASDAQ: KROS) with a 13.3% stake, has released an investor presentation detailing its reasons for opposing the re-election of Dr. Mary Ann Gray and Dr. Alpna Seth to the company's Board of Directors. The decision will be voted on at Keros' Annual Meeting of Stockholders scheduled for June 4, 2025.

Keros Therapeutics (NASDAQ: KROS), a clinical-stage biopharmaceutical company specializing in TGF-ß family protein signaling disorders, has announced its participation in the Bank of America 2025 Global Healthcare Conference. The company's CEO, Jasbir S. Seehra, Ph.D., will engage in a fireside chat presentation on May 13, 2025, at 8:00 p.m. Eastern time. The presentation will be accessible via live webcast, with a replay available on the company's investor relations website for 90 days after the event.

Keros Therapeutics (NASDAQ: KROS) has responded to ADAR1 Capital Management's recent communications regarding the upcoming 2025 Annual Meeting. The company's Board announced it is conducting a strategic review process through an independent committee to evaluate options including a potential sale, continued pipeline investment, or return of capital to shareholders. The review follows a significant $200 million upfront payment from a licensing deal with Takeda, which could yield up to $1.1 billion in additional milestones plus royalties.

ADAR1 has opposed the re-election of two independent directors unless their CIO is added to the Board, pushing for immediate capital return to shareholders. Keros's Board, comprising nine directors (eight independent), recommends shareholders vote "FOR" its three director nominees at the June 4, 2025 Annual Meeting. The company highlights its strong cash position, funding operations into 2029.

ADAR1 Capital Management, Keros Therapeutics' (NASDAQ: KROS) largest stockholder with a 13.3% stake, has released an open letter expressing concerns about the company's performance and direction. The activist investor announced plans to withhold votes for directors Dr. Mary Ann Gray and Dr. Alpna Seth at the June 4, 2025 stockholder meeting.

ADAR1 criticizes Keros for concerning clinical results in two drug candidates (KER-012 and KER-065) and calls for major restructuring, including a 70% headcount reduction and return of excess capital to shareholders. The company holds over $720 million in cash as of March 31, 2025. ADAR1 believes their proposed changes could deliver $24-35 per share in value, focusing on KER-050's partnership with Takeda, which they estimate could achieve $2 billion in peak sales.

Keros Therapeutics (NASDAQ: KROS) reported strong Q1 2025 financial results, posting a net income of $148.5 million compared to a net loss of $43.1 million in Q1 2024. The company's cash position strengthened to $720.5 million, expected to fund operations into 2029. Research and development expenses increased to $48.7 million, up from $38.3 million year-over-year. The company achieved significant milestones, including positive Phase 1 results for KER-065, with plans to advance to Phase 2 trials in Q1 2026. Additionally, Keros expects to report data from the Phase 2 TROPOS trial for cibotercept in Q2 2025. The Board is currently evaluating strategic alternatives to enhance stockholder value while maintaining focus on pipeline development.

Keros Therapeutics (NASDAQ: KROS) has announced that its Board of Directors has initiated a formal strategic alternatives review process to maximize stockholder value. The review will be overseen by a newly formed Strategic Committee of independent directors who will evaluate options including:

• potential sale of the company
• business combination transactions
• continued pipeline investment
• return of excess capital to stockholders

Additionally, the Board has implemented a -duration stockholder rights plan ('poison pill') in response to significant stock accumulations, including an 11.2% stake by an individual investor as of April 6, 2025. The rights plan triggers if any entity acquires 10% ownership (15% for passive institutional investors) without Board approval. The plan expires on April 9, 2026. The company expects to provide a preliminary update on the strategic review within 60 days.

Keros Therapeutics (NASDAQ: KROS) has announced positive initial topline results from its Phase 1 clinical trial of KER-065 in healthy volunteers. The trial successfully met its key objectives for safety, tolerability, and pharmacological measures through the multiple ascending dose treatment period.

Key findings as of February 6, 2025, showed that KER-065 was generally well-tolerated with no serious adverse events or dose-limiting toxicities. The drug demonstrated evidence of activin inhibition through:

• Increases in bone formation biomarkers and decreases in bone resorption markers
• Positive changes in fat mobilization biomarkers
• Improvements in body composition, including increased bone mineral density and muscle mass

Based on these results, Keros plans to engage with regulatory authorities in Q3 2025 and aims to initiate a Phase 2 clinical trial for Duchenne muscular dystrophy (DMD) patients in Q1 2026.

Keros Therapeutics (Nasdaq: KROS), a clinical-stage biopharmaceutical company specializing in TGF-ß family protein signaling disorders, has announced its upcoming participation in two major healthcare conferences.

The company's Chair and CEO, Jasbir S. Seehra, Ph.D., will present at:

• The TD Cowen 45th Annual Healthcare Conference on March 3, 2025, at 9:50 a.m. ET
• The Leerink Partners Global Healthcare Conference on March 10, 2025, at 1:40 p.m. ET

Both presentations will be in a fireside chat format, with archived replays available on the Keros website's Investor section for 90 days post-event.